Preventive effects of different probiotic formulations on travelers' diarrhea model in wistar rats : preventive effects of probiotics on TD.
A new animal model of travelers' diarrhea has been developed by infecting rats orally with a strain of enterotoxigenic Escherichia coli in order to assess the efficacy of three probiotic formulations for the prevention of travelers' diarrhea. Five groups of six rats were given daily (by oral gavage) either a placebo (negative and positive control groups), the suspension of bacterial probiotics called FF1, the yeast probiotic Saccharomyces boulardii, or a combination of both, called Protecflor(TM). After 14 days of treatment, all groups except the negative control one were infected by oral administration of E. coli. Body temperature, body weight, food and water consumption, stools consistency, behavior, and cytokines secretion were disturbed following E. coli infection. Probiotics-treated groups generally displayed less-pronounced symptoms, the combination of probiotics Protecflor(TM) being the most effective.
ETAP-Ethologie Appliquée, Département de Cancérologie et Pathologies Humaines, Centre de Recherche en Pharmacologie, Cancérologie-Pathologies Humaines et Nutrition-Santé, 13 rue du Bois de la Champelle, 54500, Vandoeuvre-lès-Nancy, France. jfbisson@etap-lab.com
Jean-François
JF
Bisson
Sophie
S
Hidalgo
Pascale
P
Rozan
Michaël
M
Messaoudi
D000284:Administration, Oral; D000818:Animals; D016207:Cytokines / Q000097:blood; D003967:Diarrhea / Q000276:immunology / Q000517:prevention & control*; D004195:Disease Models, Animal; D054307:Enterotoxigenic Escherichia coli; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D011292:Premedication; D019936:Probiotics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014195:Travel
D016207:Cytokines